Promising Long-Term Remission in Advanced Liver Cancer Patients Using Combination Therapy

A groundbreaking study by researchers from The University of Hong Kong has revealed that a novel combination therapy, integrating locoregional treatment with immunotherapy (LRT-IO), can induce long-lasting remission in patients with advanced liver cancer. This research, the first of its kind to examine long-term outcomes, demonstrates that nearly half of treated patients achieved complete tumor response, with over 60% of these remaining cancer-free for extended periods. The approach involves a combination of stereotactic beam radiotherapy (SBRT), optional transarterial chemoembolization (TACE), followed by immunotherapy, and shows promise as a potentially curative option for cancers previously deemed intractable.

The study tracked 63 patients with unresectable liver tumors over nearly three years. Results showed that 46% achieved complete response, with most remaining cancer-free months later. Patients who responded fully had a significantly higher three-year survival rate (76%) compared to non-responders (28%), with survival rates comparable to those who had undergone surgery. Even among recurrences, many were suitable candidates for curative surgery, highlighting the potential of the treatment to convert inoperable to operable cases.

This research supports the growing evidence that the LRT-IO strategy could transform the management of advanced liver cancer. Notably, it provides hope for elderly, medically unfit, or difficult-to-operate patients, for whom traditional surgery isn’t feasible. The findings have influenced national guidelines in China and are increasingly adopted by clinical centers in Hong Kong. Experts believe this approach, along with watch-and-wait strategies for responders, could significantly improve long-term outcomes and even lead to cures.

The study’s success underscores the importance of integrating innovative therapies to tackle one of the most challenging cancers, providing new avenues for management and potential cure of advanced liver cancer.